Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 1.80% is 52% below its 5-year average of 3.75%, near the low end of its 5-year range (0.34%–9.99%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.46% below its 12-month average of 3.36%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 1.80%.
DEBT TO ASSETS RATIO
1.80%
DEBT TO ASSETS RATIO AVG TTM
3.36%
DEBT TO ASSETS RATIO AVG 3Y
4.74%
DEBT TO ASSETS RATIO AVG 5Y
3.75%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-46.46%
CURRENT VS 3Y AVG
-62.03%
CURRENT VS 5Y AVG
-52.02%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 660 covered companies
CURRENT VS SECTOR MEDIAN
+1698.32%
vs the sector median at left
Immuneering Corporation
Market Cap
$145.75M
Debt to Assets Ratio
1.80%
TTM Avg
3.36%
3Y Avg
4.74%
5Y Avg
3.75%
Market Cap
$145.67M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$147.54M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$142.15M
Debt to Assets Ratio
0.36%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$149.87M
Debt to Assets Ratio
0.27%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$139.73M
Debt to Assets Ratio
0.20%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$151.52M
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $145.75M | 1.80% | 3.36% | 4.74% | 3.75% |
| Korsana Biosciences, Inc. (KRSA)vs › | $145.67M | 0.00% | N/A | N/A | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $147.54M | 0.00% | N/A | N/A | N/A |
| LifeMD, Inc. (LFMDP)vs › | $147.97M | 0.10% | N/A | N/A | N/A |
| Nyxoah S.A. (NYXH)vs › | $143.09M | 0.31% | N/A | N/A | N/A |
| AirSculpt Technologies, Inc. (AIRS)vs › | $142.15M | 0.36% | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $149.87M | 0.27% | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $139.73M | 0.20% | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $151.52M | 0.00% | N/A | N/A | N/A |
| Alpha Cognition Inc (ACOG)vs › | $139.63M | 0.00% | N/A | N/A | N/A |
Debt/Assets
1.8%
Debt/Equity
0.02
Current Ratio
19.47
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 1.80% |
| 2026-03-31 | 1.74% |
| 2025-12-31 | 1.65% |
| 2025-09-30 | 1.62% |
| 2025-06-30 | 9.99% |
| 2025-03-31 | 8.06% |
| 2024-12-31 | 7.90% |
| 2024-09-30 | 6.19% |
| 2024-06-30 | 5.59% |
| 2024-03-31 | 4.98% |
| 2023-12-31 | 4.35% |
| 2023-09-30 | 3.99% |
| 2023-06-30 | 3.72% |
| 2023-03-31 | 4.41% |
| 2022-12-31 | 3.96% |
| 2022-09-30 | 3.63% |
| 2022-06-30 | 3.47% |
| 2022-03-31 | 3.26% |
| 2021-12-31 | 3.22% |
| 2021-09-30 | 0.34% |
| 2021-06-30 | 1.10% |
| 2021-03-31 | 1.83% |
| 2020-12-31 | 1.62% |
